Recent Trends in Adjuvant Therapy for Gastric Cancer

1992 ◽  
Vol 15 (2) ◽  
pp. 102-110 ◽  
Author(s):  
M. Lise ◽  
D. Nitti ◽  
A. Marchet ◽  
F. Farinati ◽  
M. Buyse ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Recent Trends

703 Adjuvant Therapy Completion Rates in Patients With Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach

2015 ◽  
Vol 148 (4) ◽  
pp. S-1118-S-1119 ◽  
Author(s):  
Eva Fuentes ◽  
Rima Ahmad ◽  
Theodore S. Hong ◽  
Eunice L. Kwak ◽  
David W. Rattner ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Perioperative Chemotherapy ◽  
Completion Rates ◽  
Surgery First ◽  
Therapy Completion

Defining a High-Risk Subgroup of Pathological T2N0 Gastric Cancer by Prognostic Risk Stratification for Adjuvant Therapy

2011 ◽  
Vol 15 (12) ◽  
pp. 2153-2158 ◽  
Author(s):  
Chunyan Du ◽  
Ye Zhou ◽  
Kai Huang ◽  
Guangfa Zhao ◽  
Hong Fu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Risk Stratification

scholarly journals A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial

2018 ◽  
Vol 21 (5) ◽  
pp. 811-818 ◽  
Author(s):  
Kazuhiro Nishikawa ◽  
Akira Tsuburaya ◽  
Takaki Yoshikawa ◽  
Masazumi Takahashi ◽  
Kazuaki Tanabe ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Early Relapse

Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions

2012 ◽  
pp. e31-e34
Author(s):  
Yoon-Koo Kang ◽  
Changhoon Yoo
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Standard Of Care ◽  
Current Standard ◽  
The West ◽  
The United Kingdom ◽  
Group B ◽  
Leukemia Group ◽  
Postoperative Chemoradiation

Overview: After much debate, adjuvant therapy has become the standard of care worldwide for resected localized gastric cancer. However, geographic differences exist in standard adjuvant treatments: postoperative chemoradiation in North America, perioperative chemotherapy in the United Kingdom, and postoperative chemotherapy in East Asia. Now that D2 gastrectomy has been recognized as the optimal surgery for localized gastric cancer in the West as well as in Asia, the standard adjuvant treatments used in the West may need to be reconsidered. One of the most important issues in adjuvant therapy for localized gastric cancer is how to improve the clinical outcomes of current standard treatments. Recent Cancer and Leukemia Group B (CALGB) and AMC studies suggest that simply intensifying chemotherapy by adding more agents or prolonging treatment duration is insufficient. However, new strategies like early initiation of chemotherapy and/or intraperitoneal chemotherapy may further improve the current standard adjuvant therapy. In the era of targeted therapy, the role of biologic agents for gastric cancer should also be explored in the adjuvant setting. With a deeper understanding of the molecular biology of gastric cancer, adjuvant therapy for patients with localized gastric cancer can be optimized and individualized.

Chemosensitivity test using collagen gel droplet-embedded culture may predict effectiveness of adjuvant therapy for gastric cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4218-4218
Author(s):  
T. Nishida ◽  
M. Yoshikawa ◽  
T. Kitagawa ◽  
T. Ito ◽  
H. Matsuda
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Therapy ◽  
Collagen Gel ◽  
Chemosensitivity Test
Sign in / Sign up

Export Citation Format

Share Document